Actavis CEO sees no urgent deal pressure; Merck to appeal $4.6M jury verdict;

 @FiercePharma: Private payers battle high-tech drug costs, too. Story | Follow @FiercePharma

> Icelandic drugmaker Actavis expects record results in 2010 and is under no pressure in the short term to sell or float the company, its chief executive told Reuters. Story

> Merck said it will appeal a jury verdict in a pricing case, which orders the company to pay $4.6 million to the Commonwealth of Massachusetts. Report

> Sanofi-Aventis (SASY.PA) said new trial data showed its Jevtana drug in combination with prednisone improved the survival rate in advanced prostate cancer patients. Report

> The Johnson & Johnson children's drug set to return to the market after a major recall earlier this year is grape-flavored Liquid Children's Tylenol, made at a plant in Guelph, Canada. News

> The FDA declined to approve Teva Pharmaceutical Industries' application to sell a copycat version of Amgen's Neupogen, effectively delaying any launch of the company's first generic biotech drug sold in the U.S. Article

> Elan said it bought back $155 million in senior notes due in 2013. Item

Biotech News

 @FierceBiotech: Sanofi ejects two R&D sites, forges $2.2B pact with Covance. Report | Follow @FierceBiotech

> FDA wants more data on Teva's Neupogen biosimilar. Story

> FDA sets out clinical trial safety rules. Report

And Finally... The Prempro trial judge in Arkansas uses his experience with mules to deal with stubborn lawyers. Article

Suggested Articles

The eight-year deal will initially cover lupus drug Benlysta and could expand to other GSK specialty-care products in the future.

Amarin had big plans for Vascepa after a big label expansion last year, but it lost a patent fight—and now a generic has won FDA approval.

Intercept Pharmaceuticals, eager to market its potential nonalcoholic steatohepatitis medicine obeticholic acid, will have to keep waiting.